Schwab Charles Investment Management Inc. acquired a new stake in Sientra, Inc. (NASDAQ:SIEN) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 25,900 shares of the medical instruments supplier’s stock, valued at approximately $252,000. Schwab Charles Investment Management Inc. owned about 0.14% of Sientra at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of SIEN. Gilder Gagnon Howe & Co. LLC grew its stake in Sientra by 36.3% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,114,511 shares of the medical instruments supplier’s stock valued at $10,833,000 after acquiring an additional 296,902 shares during the period. Morgan Stanley grew its stake in Sientra by 449.6% in the first quarter. Morgan Stanley now owns 128,358 shares of the medical instruments supplier’s stock valued at $1,081,000 after acquiring an additional 105,005 shares during the period. Creative Planning grew its stake in Sientra by 639.1% in the second quarter. Creative Planning now owns 34,000 shares of the medical instruments supplier’s stock valued at $330,000 after acquiring an additional 29,400 shares during the period. Renaissance Technologies LLC acquired a new position in Sientra in the first quarter valued at about $224,000. Finally, KCG Holdings Inc. acquired a new position in Sientra in the first quarter valued at about $147,000. 77.59% of the stock is owned by hedge funds and other institutional investors.

Sientra, Inc. (SIEN) opened at $13.50 on Friday. Sientra, Inc. has a 52-week low of $7.20 and a 52-week high of $16.68. The company has a quick ratio of 1.85, a current ratio of 2.87 and a debt-to-equity ratio of 0.57.

Sientra (NASDAQ:SIEN) last released its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.06). The business had revenue of $9.80 million during the quarter, compared to the consensus estimate of $10.54 million. Sientra had a negative net margin of 169.77% and a negative return on equity of 68.82%. Sientra’s quarterly revenue was up 50.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.55) EPS. research analysts predict that Sientra, Inc. will post -3.07 earnings per share for the current fiscal year.

A number of research firms have issued reports on SIEN. Lake Street Capital reissued a “buy” rating and issued a $15.00 target price (up from $11.00) on shares of Sientra in a research note on Tuesday, August 8th. Stifel Nicolaus reaffirmed a “hold” rating and set a $14.00 price objective (up from $11.00) on shares of Sientra in a research report on Wednesday, September 27th. Zacks Investment Research cut Sientra from a “hold” rating to a “sell” rating in a research report on Tuesday, August 15th. Canaccord Genuity reaffirmed a “buy” rating and set a $14.00 price objective on shares of Sientra in a research report on Sunday, October 8th. Finally, William Blair raised Sientra from a “market perform” rating to an “outperform” rating in a research report on Wednesday, September 13th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. Sientra currently has an average rating of “Hold” and an average price target of $13.75.

TRADEMARK VIOLATION NOTICE: “Schwab Charles Investment Management Inc. Acquires New Holdings in Sientra, Inc. (SIEN)” was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.watchlistnews.com/schwab-charles-investment-management-inc-acquires-new-holdings-in-sientra-inc-sien/1694770.html.

Sientra Profile

Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.

Institutional Ownership by Quarter for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.